# US 2021/0069253 A1 · Recombinant adenoviruses and stem cells comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069253 A1
- Document ID: US20210069253A1
- Status: Published application
- Kind: A1
- Application number: 16/772,033
- Filed: 2018-12-12
- Published: 2021-03-11
- Earliest claimed: 2017-12-13
- Assignees: Genemedicine Co., Ltd.
- Applicants: Genemedicine Co., Ltd.
- Inventors: Chae Ok YUN; Yan LI
- Web page: https://patentgrep.com/patent/US20210069253A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/761: Adenovirus
- A61P 35/00: Antineoplastic agents
- C12N 5/0662: {Stem cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2510/00: Genetically modified cells
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10345: Special targeting system for viral vectors
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.

## Claims

### Claim 1

A mesenchymal stem cell (MSC) for anticancer comprising a recombinant adenovirus comprising a target gene and a sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The mesenchymal stem cell for anticancer of claim 1, wherein the recombinant adenovirus further comprises a gene expression regulatory sequence that regulates the expression of the target gene.

### Claim 3 (depends on 2)

The mesenchymal stem cell for anticancer of claim 2, wherein the gene expression regulatory sequence comprises an AFP promoter sequence of SEQ ID NO: 5 or a TERT promoter sequence of SEQ ID NO: 8.

### Claim 4 (depends on 1)

The mesenchymal stem cell for anticancer of claim 1, wherein the mesenchymal stem cell is infected for 50 hours or less with a recombinant adenovirus comprising the target gene and the sequence of SEQ ID NO: 1 at a concentration of greater than 0.01 MOI to less than 100 MOI.

### Claim 5

A composition for delivering a gene, the composition comprising a mesenchymal stem cell in which a recombinant adenovirus comprising a target gene and a sequence of SEQ ID NO: 1 is loaded.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the recombinant adenovirus further comprises a gene expression regulatory sequence that regulates the expression of the target gene.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the composition is for systemic administration or local administration.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the composition comprises a mesenchymal stem cell infected for 50 hours or less with a recombinant adenovirus comprising the target gene and the sequence of SEQ ID NO: 1 at a concentration of greater than 0.01 MOI to less than 100 MOI.

### Claim 9

A pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a pharmaceutically effective amount of a mesenchymal stem cell (MSC) in which a recombinant adenovirus comprising a target gene and a sequence of SEQ ID NO: 1 is loaded.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the recombinant adenovirus further comprises a gene expression regulatory sequence that regulates the expression of the target gene.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the composition comprises a mesenchymal stem cell infected for 50 hours or less with a recombinant adenovirus comprising the target gene and the sequence of SEQ ID NO: 1 at greater than 0.01 MOI to less than 100 MOI.

### Claim 12

A recombinant adenovirus with enhanced stem cell transduction potency comprising a serotype 35 fiber knob.

### Claim 13 (depends on 12)

The recombinant adenovirus of claim 12, wherein the serotype 35 fiber knob consists of a sequence of SEQ ID NO: 1.

### Claim 14 (depends on 12)

The recombinant adenovirus of claim 12, wherein the recombinant adenovirus further comprises a target gene and a gene expression regulatory sequence that regulates the expression of the target gene.

### Claim 15 (depends on 12)

The recombinant adenovirus of claim 12, wherein the recombinant adenovirus comprises: a gene expression regulatory sequence comprising, in a 5′ to 3′ direction, (a) a sequence of 6 copies of a hypoxia-response element (HRE), (b) a sequence of 2 copies of alpha-fetoprotein (AFP) enhancer A, (c) a sequence of one copy of AFP promoter enhancer B, and (d) an AFP promoter sequence or a TERT promoter sequence; a target gene that is operatively linked to the gene expression regulatory sequence; and a serotype 35 fiber knob sequence.
